Xanomeline (LY-246708) is an orally bioavailable, brain-penetrant M1/M4 muscarinic receptor agonist used in research for neurological disorders like schizophrenia. It has been investigated in both in vitro binding assays and in vivo preclinical models, demonstrating potential pro-cognitive and antipsychotic-like effects.